Who
David W. Boyer
Chief Corp. Affairs Officer
Company insider
Files Form 4 as: Chief Corp. Affairs Officer, Neurocrine Biosciences.
In numbers
- Trades disclosed
- 81
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $7.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 Feb 2022
- Last trade
- 14 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $130K826 at $157.45 | filing |
| 14 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $130K826 at $157.45 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —3,587 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $302K1,936 at $156.22 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —3,587 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $302K1,936 at $156.22 | filing |
| 26 May 2026filed 28 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $609K3,888 at $156.64 | filing |
| 26 May 2026filed 28 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $609K3,888 at $156.64 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,541 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,811 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,234 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,479 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —1,541 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,541 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,811 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,234 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,479 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $103K832 at $124.12 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —1,811 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $121K978 at $124.12 | filing |
News
Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)NBIX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name David W. Boyer; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.